Features | Partner Sites | Information | LinkXpress
Sign In
GLOBETECH PUBLISHING LLC
PURITAN MEDICAL
GLOBETECH PUBLISHING LLC

New Cell and Tissue Acquisition Device Improves Efficiency at More Affordable Price

By BiotechDaily International staff writers
Posted on 26 Feb 2013
Image: Kuiqpick—the new cell and tissue acquisition system from NeuroInDx (Photo courtesy of NeuroInDx).
Image: Kuiqpick—the new cell and tissue acquisition system from NeuroInDx (Photo courtesy of NeuroInDx).
An innovative and affordable new cell and tissue acquisition instrument improves efficiency and ease-of-use compared to existing laser-assisted microdissection systems.

Kuiqpick, introduced by NeuroInDx, Inc. (Los Angeles, CA, USA), is the innovative new laser-assisted microdissection and acquisition system for research laboratories. It includes the additional the capacity to collect cells from tissues and cultures without affecting their viability, enabling the collected cells to then be cultured for further analysis and downstream applications. Also notable, Kuiqpick costs less than USD 30,000 per device, about one-fourth the cost of existing systems. “Kuiqpick [opens] the door for more labs to conduct the critical collection of live cells and tissue areas for examination and culturing,” said Stan Karsten, PhD, NeuroInDx chief scientific officer and cofounder; “For too long, the high cost of tissue microdissection and cell sorting technologies have limited cell-specific research. With the introduction of Kuiqpick, more labs and researchers can afford the technology.”

Rebecca Stockton, PhD, a University of California, Los Angeles (UCLA) assistant professor of pediatrics, uses Kuiqpick to study cerebral cavernous malformations and said, “[Kuiqpick is] perfect for collecting small abnormal blood vessels from the brain tissue and specific cells from cultures based on their form and structure, or their morphology, which is critical for my research.”

Originally conceived at UCLA and further developed by NeuroInDx, Kuiqpick can be attached to an inverted microscope to dissect brain tissue slices at the cellular resolution and collect individual cells from various cell cultures. A single press of a button initiates the collection of the brain tissue area or cells into a disposable capillary unit. Collected tissue samples are then transferred to a test tube for further use. “Kuiqpick is a novel and highly accurate system that has already proven to be extremely efficient in the isolation of specific cell populations from live and freshly frozen brain tissues,” said Dr. Lili C. Kudo, president and CEO of NeuroInDx; “It can be successfully used in a variety of molecular studies, including stem cell research, genomics and proteomics.”

NeuroInDx also offers to provide researchers with custom cell and tissue collection services and subsequent gene expression-microarray experiments, thus saving time and funding for their projects.

Related Links:

NeuroInDx





Channels

Genomics/Proteomics

view channel
Image: Researchers have generated disease-free stem cells from patients with mitochondrial disease that can be converted into any cell type including neuronal progenitors (left) or heart cells (right). These could potentially be used for future transplantation into patients (Photo courtesy of Salk Institute of Biological Studies).

Methods Developed to Generate Normal Stem Cells from Patients with Mitochondrial Defects

A recent paper described two methods for converting cells from patients with mitochondrial defects into normal pluripotent stem cells that could be induced to differentiate into several different types of tissues.... Read more

Drug Discovery

view channel
Image: A new micelle delivery system for the protective polyphenols resveratrol and quercetin (mRQ) may have value in cancer chemotherapy (Photo courtesy of Oregon State University).

Micelles Containing Resveratrol and Quercetin Reverse Doxorubicin Cardiotoxicity

Cancer researchers blocked the toxic effects of the cancer drug doxorubicin (DOX) by administering it together with the plant antioxidants resveratrol and quercetin. Although in use for more than 40... Read more

Business

view channel

Teva Buys Allergan Generic Business Unit

Teva Pharmaceutical Industries (Petah Tikva, Israel) has bought the Allergan (Irvine, CA, USA) generic drugs business for USD 40.5 billion in cash and stock, solidifying its position as the world's largest generic drug maker. Under the terms of the agreement, Teva will pay USD 33.75 billion in cash and USD 6.... Read more
 
Copyright © 2000-2015 Globetech Media. All rights reserved.